Rank 65 • AI & Clinical Intelligence
ArteraAI
Develops AI-enabled prognostic tests to personalize cancer therapy decisions and predict therapeutic benefits for patients.
Visit website- Signal Score
- 84.7
- Total raised
- $115M
- Stage
- Series B
- Founded
- 2021
- Headquarters
- San Francisco, USA
- Region
- North America
Their signal
ArteraAI is a rising star in digital pathology, securing substantial funding and clinical validation for its multimodal AI test that predicts prostate cancer outcomes.
Signal Score 84.7editorial estimate, see how it is built
Total raised, quality of investors and recency of the last round.
Revenue trajectory, customer count, hiring and market pull.
Peer-reviewed evidence, FDA/CE clearances and live health-system deployments.
Founder track record, clinical depth on the bench and technical leadership.
Search presence, press coverage, founder and brand reach, and how often the company shows up where buyers look.
Also in AI & Clinical Intelligence
Did we miss something?
Change, add or remove details on this company. Our desk reviews every request.
Figures are subjective research desk estimates compiled from public sources and refreshed monthly, published as editorial commentary. Company marks are shown for identification only and imply no endorsement or affiliation. Want a correction, an update or removal? and see our corrections and removals policy.